Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | PTAFR | P25105 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5619731 | 1.00 | TACR1 (0.52) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL5619448 | 1.00 | TACR1 (0.52) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL5618497 | 0.89 | TACR1 (0.49) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL5618546 | 0.89 | TACR1 (0.49) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL5618500 | 0.89 | TACR1 (0.49) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL5618540 | 0.88 | TACR1 (0.47) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL6365455 | 0.88 | TACR1 (0.47) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL5618542 | 0.88 | TACR1 (0.47) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL2486644 | 0.87 | TACR1 (0.67) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL3317448 | 0.87 | TACR1 (0.67) | TACR1SIGMAR1PTAFRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276509-B2 | Piperidine derivatives and their use as antagonists of tachykinins | GLAXO GROUP LIMITED (GB) | 2007-10-02 | — | — | US | claimed |
| US-20050096313-A1 | Piperidine derivatives and their use as antagonists of tachykinins | GLAXO GROUP LIMITED (GB) | 2005-05-05 | — | — | US | claimed |
| EP-1472243-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 2004-11-03 | — | — | EP | claimed |
| WO-2003066621-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | claimed |
| US-20180021327-A1 | TREATMENT OF CORNEAL NEOVASCULARIZATION | IRBM SCIENCE PARK S.P.A. (IT) | 2018-01-25 | — | — | US | disclosed |
| US-9782397-B2 | Treatment of corneal neovascularization | IRBM SCIENCE PARK S.P.A. (IT) | 2017-10-10 | — | — | US | disclosed |
| EP-2729147-B1 | NK-1 RECEPTOR ANTAGONISTS FOR TREATING CORNEAL NEOVASCULARISATION | IRBM - SCIENCE PARK S P A (IT) | 2017-09-06 | — | — | EP | disclosed |
| EP-2729147-A1 | NK-1 RECEPTOR ANTAGONISTS FOR TREATING CORNEAL NEOVASCULARISATION | Ferrari, Giulio (IT) | 2014-05-14 | — | — | EP | disclosed |
| US-20140128395-A1 | Novel Method | IRBM SCIENCE PARK S.P.A. (IT) | 2014-05-08 | — | — | US | disclosed |
| WO-2013004766-A1 | NK-1 RECEPTOR ANTAGONISTS FOR TREATING CORNEAL NEOVASCULARISATION | FERRARI GIULIO (IT) | 2013-01-10 | — | — | WO | disclosed |
| US-7276509-B2 | Piperidine derivatives and their use as antagonists of tachykinins | GLAXO GROUP LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20050096313-A1 | Piperidine derivatives and their use as antagonists of tachykinins | GLAXO GROUP LIMITED (GB) | 2005-05-05 | — | — | US | disclosed |
| EP-1472243-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066621-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096313-A1 | Piperidine derivatives and their use as antagonists of tachykinins | NPSR1, TACR1, OPRL1 | TACR1 2/4885SIGMAR1 27/4885PTAFR 1400/4885 |
| US-20140128395-A1 | Novel Method | BAK1, VIPR1, BDKRB1 | TACR1 38/4885SIGMAR1 656/4885PTAFR 1498/4885 |
| US-20180021327-A1 | TREATMENT OF CORNEAL NEOVASCULARIZATION | KDR, BAK1, FLT1 | TACR1 119/4885SIGMAR1 929/4885PTAFR 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.